Related references
Note: Only part of the references are listed.NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence
Ash Bullement et al.
PHARMACOECONOMICS (2019)
New drugs: where did we go wrong and what can we do better?
Beate Wieseler et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
BEACON trial in colorectal cancer is single worst reported, says critic
Jacqui Wise
BMJ-BRITISH MEDICAL JOURNAL (2019)
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
Paul Emery et al.
RHEUMATOLOGY (2019)
Redactions in protocols for drug trials: what industry sponsors concealed
Mikkel Marquardsen et al.
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2018)
Contribution of NIH funding to new drug approvals 2010-2016
Ekaterina Galkina Cleary et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
EMA scales back transparency initiatives because of workload
Peter Doshi
BMJ-BRITISH MEDICAL JOURNAL (2018)
Secrecy or transparency? The future of regulatory trial data
Beate Wieseler et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward
Dimitra Panteli et al.
HEALTH RESEARCH POLICY AND SYSTEMS (2016)
Medicines transparency at the European Medicines Agency (EMA) in the new information age: the perspectives of patients
Dominic Way et al.
JOURNAL OF RISK RESEARCH (2016)
Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports
Michael Koehler et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Information and deformations
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2015)
Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports
Michael Koehler et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Information and deformations
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2015)
CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?
Karl Claxton et al.
HEALTH ECONOMICS (2015)
Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study
Peter Lurie et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Transparency and the European Medicines Agency - Sharing of Clinical Trial Data
Sergio Bonini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Lack of proportionality. Seven specifications of public interest that override post-approval commercial interests on limited access to clinical data
Daniel Strech et al.
TRIALS (2012)
Single-chamber versus dual-chamber pacing for high-grade atrioventricular block
WD Toff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
